{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:12:00Z","timestamp":1784740320118,"version":"3.55.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012910","name":"National Defense Medical College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012910","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious central nervous system complication of systemic lupus erythematosus (SLE) that markedly reduces patient quality of life. Despite its clinical importance, the underlying mechanisms remain incompletely defined, and effective treatments are limited. In this review, we synthesize preclinical and clinical evidence that aberrant activation of innate immunity by self-nucleic acids and consequent overproduction of Type I interferons (IFN-I) constitute a central pathogenic axis in NPSLE. IFN-I and other inflammatory mediators promote disruption of the blood\u2013brain barrier (BBB), enabling entry of autoantibodies, cytokines, and immune cells into the brain. These factors, together with damage-associated molecular patterns, activate microglia and astrocytes, driving sustained neuroinflammation that provokes synaptic loss, neurotransmitter dysregulation, excitotoxic neuronal injury, impaired neurogenesis, and mitochondrial dysfunction\u2014mechanisms that underlie cognitive impairment, mood disorders, and other neuropsychiatric manifestations. We review therapeutic strategies targeting each step of this cascade, including blockade of IFN-I signaling (e.g., anifrolumab), inhibition of endosomal nucleic acid sensing (TLR antagonists), cytokine and JAK inhibition, modulation of microglial function (CSF1R inhibitors), and approaches to protect or restore BBB integrity (e.g., statins). Finally, we discuss biomarker-guided patient stratification and trial designs necessary to address NPSLE heterogeneity and accelerate the development of personalized therapies. By elucidating the cellular responses of the neurovascular unit to innate immune insults, this review provides a molecular framework for developing targeted therapies for NPSLE.<\/jats:p>","DOI":"10.1007\/s13577-026-01381-5","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:53:19Z","timestamp":1776351199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation"],"prefix":"10.1007","volume":"39","author":[{"given":"Wataru","family":"Nagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7887-8150","authenticated-orcid":false,"given":"Toshiaki","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"1","key":"1381_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.it.2006.11.004","volume":"28","author":"I Galea","year":"2007","unstructured":"Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol. 2007;28(1):12\u20138. https:\/\/doi.org\/10.1016\/j.it.2006.11.004.","journal-title":"Trends Immunol"},{"issue":"5","key":"1381_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/nrn3722","volume":"15","author":"M Prinz","year":"2014","unstructured":"Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014;15(5):300\u201312. https:\/\/doi.org\/10.1038\/nrn3722.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1381_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrn2297","volume":"9","author":"R Dantzer","year":"2008","unstructured":"Dantzer R, O\u2019Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46\u201356. https:\/\/doi.org\/10.1038\/nrn2297.","journal-title":"Nat Rev Neurosci"},{"issue":"22","key":"1381_CR4","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110\u201321. https:\/\/doi.org\/10.1056\/NEJMra1100359.","journal-title":"N Engl J Med"},{"issue":"2","key":"1381_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.21571","volume":"54","author":"L R\u00f6nnblom","year":"2006","unstructured":"R\u00f6nnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 2006;54(2):408\u201320. https:\/\/doi.org\/10.1002\/art.21571.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1381_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrneurol.2014.148","volume":"10","author":"H Jeltsch-David","year":"2014","unstructured":"Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10(10):579\u201396. https:\/\/doi.org\/10.1038\/nrneurol.2014.148.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1381_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semarthrit.2010.08.001","volume":"41","author":"A Unterman","year":"2011","unstructured":"Unterman A, Nolte JE, Boaz M, Abady M, Shoenfeld Y, Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41(1):1\u201311. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.08.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1381_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0961203313512540","volume":"23","author":"EJ Zirkzee","year":"2014","unstructured":"Zirkzee EJ, Huizinga TW, Bollen EL, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23(1):31\u20138. https:\/\/doi.org\/10.1177\/0961203313512540.","journal-title":"Lupus"},{"issue":"12","key":"1381_CR9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/ard.2010.130476","volume":"69","author":"GK Bertsias","year":"2010","unstructured":"Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074\u201382. https:\/\/doi.org\/10.1136\/ard.2010.130476.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1381_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2004.025528","volume":"64","author":"L Barile-Fabris","year":"2005","unstructured":"Barile-Fabris L, Ariza-Andraca R, Olgu\u00edn-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620\u20135. https:\/\/doi.org\/10.1136\/ard.2004.025528.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1381_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41584-018-0156-8","volume":"15","author":"N Schwartz","year":"2019","unstructured":"Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol. 2019;15(3):137\u201352. https:\/\/doi.org\/10.1038\/s41584-018-0156-8.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1381_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/ar4325","volume":"15","author":"MJ Kaplan","year":"2013","unstructured":"Kaplan MJ. Role of neutrophils in systemic autoimmune diseases. Arthritis Res Ther. 2013;15(5):219. https:\/\/doi.org\/10.1186\/ar4325.","journal-title":"Arthritis Res Ther"},{"issue":"21","key":"1381_CR13","doi-asserted-by":"publisher","first-page":"9813","DOI":"10.1073\/pnas.0909927107","volume":"107","author":"A Hakkim","year":"2010","unstructured":"Hakkim A, F\u00fcrnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107(21):9813\u20138. https:\/\/doi.org\/10.1073\/pnas.0909927107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2\u20133","key":"1381_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jaut.2007.02.005","volume":"28","author":"US Gaipl","year":"2007","unstructured":"Gaipl US, Munoz LE, Grossmayer G, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun. 2007;28(2\u20133):114\u201321. https:\/\/doi.org\/10.1016\/j.jaut.2007.02.005.","journal-title":"J Autoimmun"},{"issue":"11","key":"1381_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nri1957","volume":"6","author":"A Marshak-Rothstein","year":"2006","unstructured":"Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823\u201335. https:\/\/doi.org\/10.1038\/nri1957.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1381_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","volume":"25","author":"SR Christensen","year":"2006","unstructured":"Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25(3):417\u201328. https:\/\/doi.org\/10.1016\/j.immuni.2006.07.013.","journal-title":"Immunity"},{"key":"1381_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat8657","author":"A Ablasser","year":"2019","unstructured":"Ablasser A, Chen ZJ. cGAS in action: Expanding roles in immunity and inflammation. Science. 2019. https:\/\/doi.org\/10.1126\/science.aat8657.","journal-title":"Science"},{"issue":"5421","key":"1381_CR18","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","volume":"284","author":"FP Siegal","year":"1999","unstructured":"Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284(5421):1835\u20137. https:\/\/doi.org\/10.1126\/science.284.5421.1835.","journal-title":"Science"},{"issue":"5","key":"1381_CR19","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610\u20135. https:\/\/doi.org\/10.1073\/pnas.0337679100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1381_CR20","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459\u201368. https:\/\/doi.org\/10.4049\/jimmunol.1002795.","journal-title":"J Immunol"},{"issue":"1","key":"1381_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/s0006-8993(99)01328-1","volume":"835","author":"IL Campbell","year":"1999","unstructured":"Campbell IL, Krucker T, Steffensen S, et al. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res. 1999;835(1):46\u201361. https:\/\/doi.org\/10.1016\/s0006-8993(99)01328-1.","journal-title":"Brain Res"},{"issue":"1","key":"1381_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood\u2013brain barrier. Neurobiol Dis. 2010;37(1):13\u201325. https:\/\/doi.org\/10.1016\/j.nbd.2009.07.030.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1381_CR23","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020412","volume":"7","author":"R Daneman","year":"2015","unstructured":"Daneman R, Prat A. The blood\u2013brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. https:\/\/doi.org\/10.1101\/cshperspect.a020412.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"1381_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"NJ Abbott","year":"2006","unstructured":"Abbott NJ, R\u00f6nnb\u00e4ck L, Hansson E. Astrocyte\u2013endothelial interactions at the blood\u2013brain barrier. Nat Rev Neurosci. 2006;7(1):41\u201353. https:\/\/doi.org\/10.1038\/nrn1824.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"1381_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neuron.2017.07.030","volume":"96","author":"C Iadecola","year":"2017","unstructured":"Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron. 2017;96(1):17\u201342. https:\/\/doi.org\/10.1016\/j.neuron.2017.07.030.","journal-title":"Neuron"},{"key":"1381_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.03.010","volume":"60","author":"A Varatharaj","year":"2017","unstructured":"Varatharaj A, Galea I. The blood\u2013brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1\u201312. https:\/\/doi.org\/10.1016\/j.bbi.2016.03.010.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"1381_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/2045-8118-9-23","volume":"9","author":"AC Luissint","year":"2012","unstructured":"Luissint AC, Artus C, Glacial F, Ganeshamoorthy K, Couraud PO. Tight junctions at the blood\u2013brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9(1):23. https:\/\/doi.org\/10.1186\/2045-8118-9-23.","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"1381_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2174\/157015908785777210","volume":"6","author":"SM Stamatovic","year":"2008","unstructured":"Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell\u2013cell junctions: how to \u201copen\u201d the blood\u2013brain barrier. Curr Neuropharmacol. 2008;6(3):179\u201392. https:\/\/doi.org\/10.2174\/157015908785777210.","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"1381_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s1474-4422(09)70016-x","volume":"8","author":"GA Rosenberg","year":"2009","unstructured":"Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8(2):205\u201316. https:\/\/doi.org\/10.1016\/s1474-4422(09)70016-x.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1381_CR30","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.biocel.2003.08.007","volume":"36","author":"NS Harhaj","year":"2004","unstructured":"Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol. 2004;36(7):1206\u201337. https:\/\/doi.org\/10.1016\/j.biocel.2003.08.007.","journal-title":"Int J Biochem Cell Biol"},{"key":"1381_CR31","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-pathol-051217-111018","volume":"13","author":"BA Plog","year":"2018","unstructured":"Plog BA, Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol. 2018;13:379\u201394. https:\/\/doi.org\/10.1146\/annurev-pathol-051217-111018.","journal-title":"Annu Rev Pathol"},{"key":"1381_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003748","author":"JJ Iliff","year":"2012","unstructured":"Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2. Sci Transl Med. 2012. https:\/\/doi.org\/10.1126\/scitranslmed.3003748.","journal-title":"Sci Transl Med."},{"issue":"7560","key":"1381_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337\u201341. https:\/\/doi.org\/10.1038\/nature14432.","journal-title":"Nature"},{"issue":"6","key":"1381_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/ana.24271","volume":"76","author":"BT Kress","year":"2014","unstructured":"Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76(6):845\u201361. https:\/\/doi.org\/10.1002\/ana.24271.","journal-title":"Ann Neurol"},{"issue":"12","key":"1381_CR35","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s11064-015-1581-6","volume":"40","author":"NA Jessen","year":"2015","unstructured":"Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The glymphatic system: a beginner\u2019s guide. Neurochem Res. 2015;40(12):2583\u201399. https:\/\/doi.org\/10.1007\/s11064-015-1581-6.","journal-title":"Neurochem Res"},{"issue":"1","key":"1381_CR36","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-024-03085-9","volume":"21","author":"J Reynolds","year":"2024","unstructured":"Reynolds J, Huang M, Li Y, et al. Constitutive knockout of interleukin-6 ameliorates memory deficits and entorhinal astrocytosis in the MRL\/lpr mouse model of neuropsychiatric lupus. J Neuroinflamm. 2024;21(1):89. https:\/\/doi.org\/10.1186\/s12974-024-03085-9.","journal-title":"J Neuroinflamm"},{"issue":"1","key":"1381_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12987-025-00628-x","volume":"22","author":"JA Reynolds","year":"2025","unstructured":"Reynolds JA, Torz L, Cummins L, Stock AD, Ben-Zvi A, Putterman C. Blood\u2013CSF barrier clearance of ABC transporter substrates is suppressed by interleukin-6 in lupus choroid plexus spheroids. Fluids Barriers CNS. 2025;22(1):15. https:\/\/doi.org\/10.1186\/s12987-025-00628-x.","journal-title":"Fluids Barriers CNS"},{"issue":"4","key":"1381_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/jci58644","volume":"122","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest. 2012;122(4):1164\u201371. https:\/\/doi.org\/10.1172\/jci58644.","journal-title":"J Clin Invest"},{"issue":"1","key":"1381_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrn2038","volume":"8","author":"ML Block","year":"2007","unstructured":"Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8(1):57\u201369. https:\/\/doi.org\/10.1038\/nrn2038.","journal-title":"Nat Rev Neurosci"},{"issue":"Pt A","key":"1381_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainres.2015.09.021","volume":"1641","author":"T Zeis","year":"2016","unstructured":"Zeis T, Enz L, Schaeren-Wiemers N. The immunomodulatory oligodendrocyte. Brain Res. 2016;1641(Pt A):139\u201348. https:\/\/doi.org\/10.1016\/j.brainres.2015.09.021.","journal-title":"Brain Res"},{"key":"1381_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102608","volume":"96","author":"SL Lin","year":"2025","unstructured":"Lin SL, Carroll MC. Neuroimmune mechanisms of neuropsychiatric systemic lupus erythematosus. Curr Opin Immunol. 2025;96:102608. https:\/\/doi.org\/10.1016\/j.coi.2025.102608.","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"1381_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nri2873","volume":"10","author":"GY Chen","year":"2010","unstructured":"Chen GY, Nu\u00f1ez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826\u201337. https:\/\/doi.org\/10.1038\/nri2873.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1381_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nri2215","volume":"8","author":"H Kono","year":"2008","unstructured":"Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8(4):279\u201389. https:\/\/doi.org\/10.1038\/nri2215.","journal-title":"Nat Rev Immunol"},{"issue":"6894","key":"1381_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature00858","volume":"418","author":"P Scaffidi","year":"2002","unstructured":"Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191\u20135. https:\/\/doi.org\/10.1038\/nature00858.","journal-title":"Nature"},{"issue":"3","key":"1381_CR45","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1523\/jneurosci.3732-10.2011","volume":"31","author":"HM Gao","year":"2011","unstructured":"Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 2011;31(3):1081\u201392. https:\/\/doi.org\/10.1523\/jneurosci.3732-10.2011.","journal-title":"J Neurosci"},{"key":"1381_CR46","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3389\/fnins.2018.00628","volume":"12","author":"YN Paudel","year":"2018","unstructured":"Paudel YN, Shaikh MF, Chakraborti A, et al. HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci. 2018;12:628. https:\/\/doi.org\/10.3389\/fnins.2018.00628.","journal-title":"Front Neurosci"},{"key":"1381_CR47","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fimmu.2020.01057","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Son M, Diamond B. HMGB1 in systemic lupus erythematosus. Front Immunol. 2020;11:1057. https:\/\/doi.org\/10.3389\/fimmu.2020.01057.","journal-title":"Front Immunol"},{"issue":"7638","key":"1381_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481\u20137. https:\/\/doi.org\/10.1038\/nature21029.","journal-title":"Nature"},{"issue":"4","key":"1381_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrneurol.2010.17","volume":"6","author":"VH Perry","year":"2010","unstructured":"Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193\u2013201. https:\/\/doi.org\/10.1038\/nrneurol.2010.17.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"1381_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.it.2008.05.002","volume":"29","author":"HM Gao","year":"2008","unstructured":"Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008;29(8):357\u201365. https:\/\/doi.org\/10.1016\/j.it.2008.05.002.","journal-title":"Trends Immunol"},{"issue":"6","key":"1381_CR51","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397\u2013411. https:\/\/doi.org\/10.1038\/nri3452.","journal-title":"Nat Rev Immunol"},{"issue":"6005","key":"1381_CR52","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1194637","volume":"330","author":"F Ginhoux","year":"2010","unstructured":"Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841\u20135. https:\/\/doi.org\/10.1126\/science.1194637.","journal-title":"Science"},{"issue":"3","key":"1381_CR53","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.it.2007.01.005","volume":"28","author":"C Farina","year":"2007","unstructured":"Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007;28(3):138\u201345. https:\/\/doi.org\/10.1016\/j.it.2007.01.005.","journal-title":"Trends Immunol"},{"key":"1381_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152263","volume":"777","author":"W Shen","year":"2025","unstructured":"Shen W, Song S, Zhao X, Li D, Liu J, Yue S. Transcription factor RUNX2 participates in astrocyte-mediated neuropathic pain via transcriptional activation of Ccl2. Biochem Biophys Res Commun. 2025;777:152263. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152263.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1381_CR55","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1152\/physrev.00041.2013","volume":"94","author":"M Pekny","year":"2014","unstructured":"Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev. 2014;94(4):1077\u201398. https:\/\/doi.org\/10.1152\/physrev.00041.2013.","journal-title":"Physiol Rev"},{"issue":"4","key":"1381_CR56","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.neuron.2012.03.026","volume":"74","author":"DP Schafer","year":"2012","unstructured":"Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74(4):691\u2013705. https:\/\/doi.org\/10.1016\/j.neuron.2012.03.026.","journal-title":"Neuron"},{"issue":"6","key":"1381_CR57","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131(6):1164\u201378. https:\/\/doi.org\/10.1016\/j.cell.2007.10.036.","journal-title":"Cell"},{"issue":"6286","key":"1381_CR58","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer\u2019s mouse models. Science. 2016;352(6286):712\u20136. https:\/\/doi.org\/10.1126\/science.aad8373.","journal-title":"Science"},{"issue":"7659","key":"1381_CR59","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature22821","volume":"546","author":"AR Bialas","year":"2017","unstructured":"Bialas AR, Presumey J, Das A, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature. 2017;546(7659):539\u201343. https:\/\/doi.org\/10.1038\/nature22821.","journal-title":"Nature"},{"issue":"5","key":"1381_CR60","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200435","volume":"12","author":"A Luoma","year":"2025","unstructured":"Luoma A, Matilainen M, Tuisku JM, et al. Synaptic density in multiple sclerosis: an in vivo study using [(11)C]UCB-J-PET imaging. Neurol Neuroimmunol Neuroinflamm. 2025;12(5):e200435. https:\/\/doi.org\/10.1212\/nxi.0000000000200435.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"1381_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22\u201334. https:\/\/doi.org\/10.1038\/nri.2015.5.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1381_CR62","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/sj.mp.4001600","volume":"10","author":"MC Wichers","year":"2005","unstructured":"Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharp\u00e9 S, Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2005;10(6):538\u201344. https:\/\/doi.org\/10.1038\/sj.mp.4001600.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"1381_CR63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2990.2005.00655.x","volume":"31","author":"GJ Guillemin","year":"2005","unstructured":"Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer\u2019s disease hippocampus. Neuropathol Appl Neurobiol. 2005;31(4):395\u2013404. https:\/\/doi.org\/10.1111\/j.1365-2990.2005.00655.x.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"1381_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/00001756-200002070-00005","volume":"11","author":"RG Tavares","year":"2000","unstructured":"Tavares RG, Tasca CI, Santos CE, Wajner M, Souza DO, Dutra-Filho CS. Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. NeuroReport. 2000;11(2):249\u201353. https:\/\/doi.org\/10.1097\/00001756-200002070-00005.","journal-title":"NeuroReport"},{"issue":"4","key":"1381_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mp.2009.116","volume":"15","author":"CL Raison","year":"2010","unstructured":"Raison CL, Dantzer R, Kelley KW, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15(4):393\u2013403. https:\/\/doi.org\/10.1038\/mp.2009.116.","journal-title":"Mol Psychiatry"},{"issue":"7","key":"1381_CR66","doi-asserted-by":"publisher","first-page":"15150","DOI":"10.3390\/ijms160715150","volume":"16","author":"Y Li","year":"2015","unstructured":"Li Y, Eskelund AR, Zhou H, Budac DP, S\u00e1nchez C, Gulinello M. Behavioral deficits are accompanied by immunological and neurochemical changes in a mouse model for neuropsychiatric lupus (NP-SLE). Int J Mol Sci. 2015;16(7):15150\u201371. https:\/\/doi.org\/10.3390\/ijms160715150.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1381_CR67","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.nurt.2010.07.003","volume":"7","author":"ME Hamby","year":"2010","unstructured":"Hamby ME, Sofroniew MV. Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics. 2010;7(4):494\u2013506. https:\/\/doi.org\/10.1016\/j.nurt.2010.07.003.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"1381_CR68","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrd1958","volume":"5","author":"SA Lipton","year":"2006","unstructured":"Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160\u201370. https:\/\/doi.org\/10.1038\/nrd1958.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1381_CR69","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1002\/art.23399","volume":"58","author":"Y Arinuma","year":"2008","unstructured":"Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008;58(4):1130\u20135. https:\/\/doi.org\/10.1002\/art.23399.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1381_CR70","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nri2529","volume":"9","author":"B Diamond","year":"2009","unstructured":"Diamond B, Huerta PT, Mina-Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it\u2019s the antibodies. Nat Rev Immunol. 2009;9(6):449\u201356. https:\/\/doi.org\/10.1038\/nri2529.","journal-title":"Nat Rev Immunol"},{"issue":"5651","key":"1381_CR71","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1126\/science.1088417","volume":"302","author":"ML Monje","year":"2003","unstructured":"Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1760\u20135. https:\/\/doi.org\/10.1126\/science.1088417.","journal-title":"Science"},{"issue":"23","key":"1381_CR72","doi-asserted-by":"publisher","first-page":"13632","DOI":"10.1073\/pnas.2234031100","volume":"100","author":"CT Ekdahl","year":"2003","unstructured":"Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003;100(23):13632\u20137. https:\/\/doi.org\/10.1073\/pnas.2234031100.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1381_CR73","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/207504","volume":"2011","author":"M Gulinello","year":"2011","unstructured":"Gulinello M, Putterman C. The MRL\/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:207504. https:\/\/doi.org\/10.1155\/2011\/207504.","journal-title":"J Biomed Biotechnol"},{"issue":"12","key":"1381_CR74","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1136\/ard.2005.049486","volume":"65","author":"S Appenzeller","year":"2006","unstructured":"Appenzeller S, Carnevalle AD, Li LM, Costallat LT, Cendes F. Hippocampal atrophy in systemic lupus erythematosus. Ann Rheum Dis. 2006;65(12):1585\u20139. https:\/\/doi.org\/10.1136\/ard.2005.049486.","journal-title":"Ann Rheum Dis"},{"key":"1381_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929520","volume":"13","author":"L Zhao","year":"2022","unstructured":"Zhao L, Hu X, Xiao F, Zhang X, Zhao L, Wang M. Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus. Front Immunol. 2022;13:929520. https:\/\/doi.org\/10.3389\/fimmu.2022.929520.","journal-title":"Front Immunol"},{"issue":"3","key":"1381_CR76","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1912196.","journal-title":"N Engl J Med"},{"issue":"12","key":"1381_CR77","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/aps.2015.91","volume":"36","author":"YW Wu","year":"2015","unstructured":"Wu YW, Tang W, Zuo JP. Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol Sin. 2015;36(12):1395\u2013407. https:\/\/doi.org\/10.1038\/aps.2015.91.","journal-title":"Acta Pharmacol Sin"},{"key":"1381_CR78","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001100","author":"M Ringelstein","year":"2022","unstructured":"Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2022. https:\/\/doi.org\/10.1212\/nxi.0000000000001100.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1381_CR79","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202212207268","author":"LN Prakhova","year":"2022","unstructured":"Prakhova LN, Krasnov VS, Kasatkin DS, Korobko DS. Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. https:\/\/doi.org\/10.17116\/jnevro202212207268.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"10","key":"1381_CR80","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s00393-020-00836-w","volume":"79","author":"L K\u00fcbler","year":"2020","unstructured":"K\u00fcbler L, Bittmann I, Kuipers JG. Macrophage activation syndrome triggered by active systemic lupus erythematosus: successful treatment by interleukin-1 inhibition (anakinra). Z Rheumatol. 2020;79(10):1040\u20135. https:\/\/doi.org\/10.1007\/s00393-020-00836-w.","journal-title":"Z Rheumatol"},{"issue":"10381","key":"1381_CR81","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023;401(10381):1011\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(22)02546-6.","journal-title":"Lancet"},{"issue":"4","key":"1381_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0320179","volume":"20","author":"J Yin","year":"2025","unstructured":"Yin J, Hou Y, Wang C, Qin C. Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials. PLoS ONE. 2025;20(4):e0320179. https:\/\/doi.org\/10.1371\/journal.pone.0320179.","journal-title":"PLoS ONE"},{"key":"1381_CR83","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2147\/jir.S397639","volume":"16","author":"R Huo","year":"2023","unstructured":"Huo R, Huang X, Yang Y, Lin J. Potential use of Janus kinase inhibitors in the treatment of systemic lupus erythematosus. J Inflamm Res. 2023;16:1471\u20138. https:\/\/doi.org\/10.2147\/jir.S397639.","journal-title":"J Inflamm Res"},{"issue":"Pt 4","key":"1381_CR84","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/brain\/aww016","volume":"139","author":"EE Spangenberg","year":"2016","unstructured":"Spangenberg EE, Lee RJ, Najafi AR, et al. Eliminating microglia in Alzheimer\u2019s mice prevents neuronal loss without modulating amyloid-\u03b2 pathology. Brain. 2016;139(Pt 4):1265\u201381. https:\/\/doi.org\/10.1093\/brain\/aww016.","journal-title":"Brain"},{"issue":"Pt 3","key":"1381_CR85","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/brain\/awv379","volume":"139","author":"A Olmos-Alonso","year":"2016","unstructured":"Olmos-Alonso A, Schetters ST, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer\u2019s-like pathology. Brain. 2016;139(Pt 3):891\u2013907. https:\/\/doi.org\/10.1093\/brain\/awv379.","journal-title":"Brain"},{"issue":"4","key":"1381_CR86","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/strokeaha.107.498923","volume":"39","author":"J Ponce","year":"2008","unstructured":"Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39(4):1269\u201375. https:\/\/doi.org\/10.1161\/strokeaha.107.498923.","journal-title":"Stroke"},{"key":"1381_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2202-10-7","volume":"10","author":"G Cheng","year":"2009","unstructured":"Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L. Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci. 2009;10:7. https:\/\/doi.org\/10.1186\/1471-2202-10-7.","journal-title":"BMC Neurosci"},{"issue":"3","key":"1381_CR88","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/atvbaha.112.300893","volume":"33","author":"MS Kluger","year":"2013","unstructured":"Kluger MS, Clark PR, Tellides G, Gerke V, Pober JS. Claudin-5 controls intercellular barriers of human dermal microvascular but not human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(3):489\u2013500. https:\/\/doi.org\/10.1161\/atvbaha.112.300893.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1381_CR89","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/atvbaha.109.197582","volume":"30","author":"M Burek","year":"2010","unstructured":"Burek M, Arias-Loza PA, Roewer N, F\u00f6rster CY. Claudin-5 as a novel estrogen target in vascular endothelium. Arterioscler Thromb Vasc Biol. 2010;30(2):298\u2013304. https:\/\/doi.org\/10.1161\/atvbaha.109.197582.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1381_CR90","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s40168-021-01181-z","volume":"9","author":"L Hoyles","year":"2021","unstructured":"Hoyles L, Pontifex MG, Rodriguez-Ramiro I, et al. Regulation of blood-brain barrier integrity by microbiome-associated methylamines and cognition by trimethylamine N-oxide. Microbiome. 2021;9(1):235. https:\/\/doi.org\/10.1186\/s40168-021-01181-z.","journal-title":"Microbiome"},{"issue":"1","key":"1381_CR91","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12974-019-1555-8","volume":"16","author":"BP Gaire","year":"2019","unstructured":"Gaire BP, Sapkota A, Song MR, Choi JW. Lysophosphatidic acid receptor 1 (LPA(1)) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia. J Neuroinflamm. 2019;16(1):170. https:\/\/doi.org\/10.1186\/s12974-019-1555-8.","journal-title":"J Neuroinflamm"},{"issue":"4","key":"1381_CR92","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1186\/ar3101","volume":"12","author":"SN Kariuki","year":"2010","unstructured":"Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(4):R151. https:\/\/doi.org\/10.1186\/ar3101.","journal-title":"Arthritis Res Ther"},{"key":"1381_CR93","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ov6027","author":"W Nagata","year":"2024","unstructured":"Nagata W, Takayama E, Nakagawa K, et al. Treatment with lysophosphatidic acid improves glomerulonephritis through the suppression of macrophage activation in a murine model of systemic lupus erythematosus. Clin Exp Rheumatol. 2024. https:\/\/doi.org\/10.55563\/clinexprheumatol\/ov6027.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"1381_CR94","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/cei\/uxad010","volume":"212","author":"W Nagata","year":"2023","unstructured":"Nagata W, Koizumi A, Nakagawa K, et al. Treatment with lysophosphatidic acid prevents microglial activation and depression-like behaviours in a murine model of neuropsychiatric systemic lupus erythematosus. Clin Exp Immunol. 2023;212(2):81\u201392. https:\/\/doi.org\/10.1093\/cei\/uxad010.","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"1381_CR95","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1535-7163.Mct-08-1106","volume":"8","author":"H Li","year":"2009","unstructured":"Li H, Wang D, Zhang H, et al. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis\/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther. 2009;8(6):1692\u2013701. https:\/\/doi.org\/10.1158\/1535-7163.Mct-08-1106.","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"1381_CR96","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.febslet.2014.02.009","volume":"588","author":"MG Benesch","year":"2014","unstructured":"Benesch MG, Ko YM, McMullen TP, Brindley DN. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions. FEBS Lett. 2014;588(16):2712\u201327. https:\/\/doi.org\/10.1016\/j.febslet.2014.02.009.","journal-title":"FEBS Lett"},{"issue":"6","key":"1381_CR97","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1007\/s13577-023-00964-w","volume":"36","author":"W Nagata","year":"2023","unstructured":"Nagata W, Gotoh M, Koizumi A, et al. Two-carba cyclic phosphatidic acid treatment promotes phenotypic switch from M1 to M2 microglia and prevents behavioral abnormalities in a mouse model of neuropsychiatric systemic lupus erythematosus. Hum Cell. 2023;36(6):2006\u201315. https:\/\/doi.org\/10.1007\/s13577-023-00964-w.","journal-title":"Hum Cell"},{"key":"1381_CR98","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/1tcgmj","author":"X Wang","year":"2025","unstructured":"Wang X, Tang J, Lu F, et al. A novel nomogram based on the identification of sTREM2 as a biomarker to predict developing neuropsychiatric systemic lupus erythematosus in lupus patients. Clin Exp Rheumatol. 2025. https:\/\/doi.org\/10.55563\/clinexprheumatol\/1tcgmj.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-026-01381-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-026-01381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T14:53:21Z","timestamp":1776351201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-026-01381-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":98,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1381"],"URL":"https:\/\/doi.org\/10.1007\/s13577-026-01381-5","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (this is a review article and did not involve human participants or animals directly).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}],"article-number":"66"}}